National Immunization Program (NIP)/Advisory Committee on Immunization Practices (ACIP) Report Stephen L. Cochi, MD, MPH Acting Director, National Immunization.

Slides:

Advertisements

Similar presentations

Immunization Services DR. KANUPRIYA CHATURVEDI DR.S.K. CHATURVEDI.

Advertisements

Module 1 Introduction to the polio endgame rationale and IPV vaccine

ACIP Meeting Update November 4 th

IPV IPV Rapidly produces high level of protective antibodies No risk of vaccine associated illness No interference from other enteroviruses. I.P.V. produces.

بسم الله الرحمن الرحيم. IRAN Vaccination policy for post eradication phase Presented by : A. R.ESTEGHAMATI, MD IRAN EPI Manager.

1 Antivirals in the Draft CDC Pandemic Plan David K. Shay Influenza Branch National Center for Infectious Diseases Centers for Disease Control and Prevention.

A global partnership to stop measles & rubella The Measles & Rubella Initiative: Preparing for the Next Decade Lisa Cairns, MD, MPH Sept 18, 2012 Washington,

1. 2 The Public Health Agency of Canada Pandemic Influenza Preparedness: An Overview Dr. Paul Gully Deputy Chief Public Health Officer Ottawa, 19 January.

CVEP Symposium: Global Vaccines 202X: Access, Equity, Ethics 2-4 May 2011 The Franklin Institute Science Museum. Philadelphia, USA Global Vaccines 202X:

HealthSanté CanadaCanada Influenza Prevention and Control in Canada Arlene King, MD, MHSc, FRCPC Director, Immunization and Respiratory Infections Division,

WHO RAP Team: Perspective and Update WORKSHOP ON ANALYZING THE POLIO ERADICATION ENDGAME, Seattle, 1-2 July 2015.

What's New on the Child and Adolescent Immunization Schedules William L. Atkinson, MD, MPH National Center for Immunization and Respiratory Diseases William.

By Laura Harrod. VFC vaccines supplied by VFC can be given only to: Children aged 18 years and younger (prior to the 19 th birthday) who: Are on Medicaid,

A program of the International Association of Immunization Managers Peer-to-Peer Exchange HPV Vaccination in Ireland Dr. Brenda Corcoran for Molly Howell,

National Immunization Program Report NVAC Washington, DC  February 3-4, 2004 Stephen L. Cochi, M.D., M.P.H. Acting Director, National Immunization Program.

A Comprehensive Policy framework for the National Immunization Programme Dr Nihal Abeysinghe, [M.B.,B.S., MSc, M.D.] Chief Epidemiologist, Ministry of.

The National Vaccine Plan Process - Update October 22, 2007 Raymond A. Strikas, MD National Vaccine Program Office Department of Health and Human Services.

The Evolving 'Polio Endgame' Strategy

Connecticut Immunization Hot Topics Teleconference Series September 2011 NANCY FENLON, RN, MS CDC National Center for Immunization and Respiratory Diseases.

Learning from the 2009 H1N1 Pandemic Response 1 Daniel S. Miller MD, MPH Director, International Influenza Unit Office of the Secretary Office of Global.

Polio End-game: What are the implications on polio vaccination policy? Dr Raju Shah.

The Challenge: How to Accelerate Eradication and the 'Endgame'?

Economic Evaluation of Routine Childhood Immunization with DTaP, Hib, IPV, MMR and HepB Vaccines in the United States, 2001 Fangjun Zhou Health Services.

State Affiliate Challenge 1 South Dakota School Nurses Association Florida Association of School Nurses Delaware School Nurse Association.

5th Annual Advocacy Project: ImmuneWise Section on Medical Students, Residents, and Fellowship Trainees

Vaccines for Children Program Stockpile Status National Vaccine Advisory Committee February 4, 2010 Washington, DC Lance E Rodewald, MD Director, Immunization.

Needs and Recommendations for the United States Poliovirus Vaccine Stockpile Report of the Joint Working Group of the National Vaccine Advisory Committee.

January 2005 Polio Eradication Initiative NVAC Meeting February Polio Eradication: Global Progress and Post-Eradication Strategies.

Vaccine-Derived Poliovirus Infections Minnesota, 2005 Jim Alexander & Jane Seward National Vaccine Advisory Committee Washington, DC February 8, 2006.

U.S. Pandemic Influenza Preparedness and Response: Update & Progress Report “The pandemic influenza clock is ticking. We just don’t know what time it is.”

Polio Eradication and End Game Strategy

1 1 Bose: SEAR Highlights and Priorities Global Measles & Rubella Management Meeting Geneva, March 2011 Accelerated Measles Control: Highlights and.

Influenza Vaccination Update for Jeanne M. Santoli, MD, MPH Deputy Director, Immunization Services Division National Center for Immunization and.

State Health Agency Perspectives on the Implementation of New Vaccines Presentation to the National Vaccine Advisory Committee September 26, 2006 Calvin.

Sustaining Polio Eradication IEAG March 2012 The experience of polio-free countries with importations of WPV: Implications for India.

Polio Eradication -- Global Progress and Development of Post-Eradication Strategies: Implications for U.S. Stockpile and Outbreak Response Preparations.

PEDIATRIC VACCINE STOCKPILES A Status Report on the Pediatric Vaccine Stockpiles November 2005 Gregory S. Wallace, M.D., M.S., M.P.H. Chief, Program Support.

TM OPV Stockpiling in the United States Trudy V. Murphy, M.D. National Immunization Program Centers for Disease Control and Prevention February 5, 2003.

Planning for the Influenza Season: Will it be Rain, Shine, or Hurricane? National Vaccine Advisory Committee June 7, 2005 Washington, DC Raymond.

2005 AHIP Immunization Assessment Summary National Vaccine Advisory Committee November 29-30, 2005 Steve Black, MD, AHIP Liaison to NVAC Bob Rehm, Director.

National Vaccine Advisory Committee Report from the Chair Gus Birkhead, MD, MPH NVAC Chair February 3, 2010.

Polio Endgame Strategy in India Considerations and Way Forward WHO-India, NPSP 15 March 2012.

A Vaccine Supply Update For The U.S. Market A Presentation At The National Vaccine Advisory Committee Meeting June 3, 2003 Dean Mason Chief, Program Support.

The changing vaccination landscape and the sources of vaccination data

National Vaccine Advisory Committee A Status Report on the Pediatric Vaccine Stockpiles Pediatric Vaccine Stockpiles February 8, 2005 Eddie Wilder Project.

Strategies to Consider to Improve ACCV Effectiveness Presentation to ACCV Vito Caserta M.D., M.P.H. Vincent Matanoski, J.D. December 5,

Global Polio Eradication Initiative The 'Intensified Effort' 18 May 2008.

A Vaccine Supply Update For The U.S. Market A Presentation At National Advisory Committee Meeting February 4, 2003 Dean Mason Chief, Program Support Branch.

VFC Pediatric Vaccine Stockpile National Vaccine Advisory Committee October 23, 2007 Gregory S. Wallace, M.D., M.S., M.P.H. Chief, Vaccine Supply and Assurance.

Adult Immunization: Goals, Challenges, and a role for the National Vaccine Advisory Committee October 22, 2007 Raymond A. Strikas, MD National Vaccine.

NVAC The Global Certification Commission declares the world polio-free when: No wild poliovirus has been found for at least 3 consecutive years.

CDC VACCINE STOCKPILE FISCAL AND MANAGEMENT ISSUES A Presentation At The National Vaccine Advisory Committee Meeting February 4, 2003 Kimberly S. Lane.

The National Vaccine Plan Update: Recent Activities and Next Steps Raymond A. Strikas, MD National Vaccine Program Office Department of Health and Human.

A global partnership to stop measles & rubella 1 Measles & Rubella Initiative --Who We Are-- Stephen Cochi, MD, MPH Global Immunization Division Centers.

February 2015 An introduction to the switch from trivalent to bivalent oral polio vaccines 1.

Job Corps Webinar: Immunizations John Kulig MD MPH Lead Medical Specialist September 29 & 30, 2010.

Module 1 Introduction to the polio endgame rationale and IPV vaccine

National Vaccine Injury Compensation Program HRSA The National Vaccine Injury Compensation Program (VICP): What’s New? National Immunization Conference.

What’s Up With All Those Other Vaccines?

Perspective and Update

World Health Organization

General guide for assessing immunizations among refugees

Emerging Gaps in Financing for New Vaccines

The Polio Eradication and Endgame Strategic Plan

2010 Tennessee Immunization Requirements for School Entrance:

المرحلة القادمة من القضاء على شلل الأطفال واللقاحات المستخدمة

Stakeholder Consultation

Women’s Health Care and Education Coalition

Preparing for the Switch

Immunization in the Era of Health Reform: What’s Next?

Presentation transcript:

National Immunization Program (NIP)/Advisory Committee on Immunization Practices (ACIP) Report Stephen L. Cochi, MD, MPH Acting Director, National Immunization Program Centers for Disease Control and Prevention National Vaccine Advisory Committee October 6, 2004

Upcoming ACIP Meeting October 27-28, 2004 Major Issues:  Influenza vaccine supply/coverage/ effectiveness  Health-care worker influenza vaccination (HICPAC-ACIP document)  Recommendations for use of meningococcal conjugate vaccine

Upcoming ACIP Meeting October 27-28, 2004 (Continued)  Review of hepatitis B vaccine use/ recommendations  Varicella epidemiology/program goals/2-dose data  Proposed evidence-based format for ACIP recommendations  Update on cardiac adverse events following smallpox vaccination

Pediatric Vaccine Stockpiles  Goal – six month supply for universally recommended vaccines for children  Target quantities currently based on birth cohort  Funding available through VFC Program  To be completed by FY 2007

Number of Doses in Millions Note: (1) Status based on recently modified targets by SWAT Team, 9/9/2004 (2) Target adjusted to reflect market demand Source: NIP data 0%0% (2) 33%79%100%7%45%33% (2) 0% % Stockpile Delivered Purchased & Delivered Additional Required For Completion, Not Purchased Current Stockpile Status(1) : Doses Delivered Vs. Target

Factors Complicating Stockpiles  Changing market share  Combination vaccines (e.g., DTaP-HepB-IPV)  Overlapping combinations (e.g., DTaP-HepB-IPV and DTaP-Hib-IPV)  Revenue recognition issues currently present a roadblock to progress

Vaccine Stockpiles Revenue Recognition “The Committee requests that the Secretary of Health and Human Services, after consultation with the Securities and Exchange Commission and other appropriate agencies, submit a report and recommendations within 90 days to the Committee. The report should include what administrative actions are being taken, solutions proposed, or identify what legislative clarification may be necessary to resolve this problem.” Source: From Senate Labor-HHS Appropriations Subcommittee Report, September 2004

Risks of Polio After Eradication' *based on current understanding RiskFrequency to date Annual burden Evolution over time VAPP 2-4/million birth cohort stable iVDPV 19 identified (since 1963) <1decreases cVDPV1* per year10increases IPV sites 1 accident (1990s) <1 decreases Lab accident 1 investigation NK decreases Deliberate 0 NK unknown After interruption of wild poliovirus, continued use of OPV will compromise the goal of a polio-free world. Expert Consultation on Vaccine-derived Polioviruses (VDPVs), Sept 2003, Geneva

Proposed Policy Decision Cessation of OPV for routine immunization Consensus of September 2003 meeting Risks > benefits in absence of wild poliovirus Expectation of countries and stakeholders High opportunity & financial costs of continued OPV. Timing: must occur while population immunity & surveillance sensitivity (for cVPDV emergence) are high. Source: David Heymann’s Polio Eradication Presentation to AACPE, 9/21/04

Conditionalities for OPV Cessation  Appropriate containment of all polioviruses.  Global surveillance & notification capacity.  mOPV stockpile & response mechanism.  Coordinated cessation of OPV.  Post OPV vaccination policy in place. Source: David Heymann’s Polio Eradication Presentation to AACPE, 9/21/04